Brief: Ultragenyx Pharma Says EC Expands Evkeeza Approval For HoFH To Children As Young As 6 Months
06/01/2025 07:20
Jan 6 (Reuters) - Ultragenyx Pharmaceutical Inc
RARE.O :
* EUROPEAN COMMISSION EXTENDS APPROVAL OF EVKEEZA TO
CHILDREN AS
YOUNG AS 6-MONTHS OLD WITH HOFH
Source text: ID:nGNEbspFcM
Further company coverage: RARE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ultragenyx Pharmaceutical
See all newsBrief: Ultragenyx Pharmaceutical Enters Settlement Agreement With Navinta On Dojolvi Patent Litigation - SEC Filing
Ultragenyx gains on $210 million US FDA voucher sale
Brief: Ultragenyx Pharmaceutical - Under Deal With U.S. Department Of Health Co To Pay 20% Of Prv Sale Proceeds To Nih
Brief: Ultragenyx Enters Into Agreement To Sell Rare Pediatric Disease Priority Review Voucher For $210 Million
U.S. STOCKS ON THE MOVE-CoreWeave, StubHub, Ultragenyx